JP2020530497A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530497A5 JP2020530497A5 JP2020530441A JP2020530441A JP2020530497A5 JP 2020530497 A5 JP2020530497 A5 JP 2020530497A5 JP 2020530441 A JP2020530441 A JP 2020530441A JP 2020530441 A JP2020530441 A JP 2020530441A JP 2020530497 A5 JP2020530497 A5 JP 2020530497A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- vol
- page
- international
- documents cited
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
- QNAQEWTWBYVVSY-UHFFFAOYSA-N 3-(1-benzofuran-3-yl)-4-(1h-indol-3-yl)pyrrole-2,5-dione Chemical class C1=CC=C2C(C=3C(=O)NC(C=3C=3C4=CC=CC=C4NC=3)=O)=COC2=C1 QNAQEWTWBYVVSY-UHFFFAOYSA-N 0.000 description 1
- FARXPFGGGGLENU-UHFFFAOYSA-N 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione Chemical compound C12=CC=3OCOC=3C=C2N(C)C=C1C1=C(C=2C3=CC(F)=CC=C3OC=2)C(=O)NC1=O FARXPFGGGGLENU-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023123302A JP7778750B2 (ja) | 2017-08-11 | 2023-07-28 | ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態 |
| JP2025168516A JP2026012715A (ja) | 2017-08-11 | 2025-10-06 | ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762544277P | 2017-08-11 | 2017-08-11 | |
| US62/544,277 | 2017-08-11 | ||
| PCT/US2018/046203 WO2019032958A1 (en) | 2017-08-11 | 2018-08-10 | SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023123302A Division JP7778750B2 (ja) | 2017-08-11 | 2023-07-28 | ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530497A JP2020530497A (ja) | 2020-10-22 |
| JP2020530497A5 true JP2020530497A5 (https=) | 2021-09-09 |
| JP7424639B2 JP7424639B2 (ja) | 2024-01-30 |
Family
ID=63405430
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530441A Active JP7424639B2 (ja) | 2017-08-11 | 2018-08-10 | ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態 |
| JP2023123302A Active JP7778750B2 (ja) | 2017-08-11 | 2023-07-28 | ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態 |
| JP2025168516A Pending JP2026012715A (ja) | 2017-08-11 | 2025-10-06 | ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023123302A Active JP7778750B2 (ja) | 2017-08-11 | 2023-07-28 | ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態 |
| JP2025168516A Pending JP2026012715A (ja) | 2017-08-11 | 2025-10-06 | ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11136334B2 (https=) |
| EP (1) | EP3665176B1 (https=) |
| JP (3) | JP7424639B2 (https=) |
| KR (3) | KR20250070131A (https=) |
| CN (2) | CN111247153B (https=) |
| AU (3) | AU2018313259B2 (https=) |
| BR (1) | BR112020002892A2 (https=) |
| CA (1) | CA3072240A1 (https=) |
| DK (1) | DK3665176T3 (https=) |
| ES (1) | ES2974328T3 (https=) |
| FI (1) | FI3665176T3 (https=) |
| IL (2) | IL313800A (https=) |
| MX (3) | MX2020001547A (https=) |
| PL (1) | PL3665176T3 (https=) |
| PT (1) | PT3665176T (https=) |
| WO (1) | WO2019032958A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3697794T (pt) * | 2017-10-16 | 2026-03-04 | Actuate Therapeutics Inc | Formas sólidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona |
| EP3793545A4 (en) * | 2018-05-17 | 2022-04-06 | Actuate Therapeutics Inc. | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS WITH BETA INHIBITORS IN THE FORM OF GLYCOGEN SYNTHASE KINASE 3 |
| JP2025525407A (ja) | 2022-06-27 | 2025-08-05 | アクチュエイト セラピューティクス インク． | エルラグルシブの経口剤形 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2446269T3 (es) | 2006-12-19 | 2014-03-06 | The Board Of Trustees Of The University Of Illinois | 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos |
| MY156701A (en) | 2009-12-23 | 2016-03-15 | Arqule Inc | Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same |
-
2018
- 2018-08-10 CN CN201880059690.4A patent/CN111247153B/zh active Active
- 2018-08-10 ES ES18760168T patent/ES2974328T3/es active Active
- 2018-08-10 JP JP2020530441A patent/JP7424639B2/ja active Active
- 2018-08-10 EP EP18760168.7A patent/EP3665176B1/en active Active
- 2018-08-10 AU AU2018313259A patent/AU2018313259B2/en active Active
- 2018-08-10 CN CN202311213594.XA patent/CN117362305A/zh active Pending
- 2018-08-10 US US16/638,303 patent/US11136334B2/en active Active
- 2018-08-10 MX MX2020001547A patent/MX2020001547A/es unknown
- 2018-08-10 KR KR1020257015420A patent/KR20250070131A/ko active Pending
- 2018-08-10 KR KR1020207006706A patent/KR102700883B1/ko active Active
- 2018-08-10 IL IL313800A patent/IL313800A/en unknown
- 2018-08-10 WO PCT/US2018/046203 patent/WO2019032958A1/en not_active Ceased
- 2018-08-10 FI FIEP18760168.7T patent/FI3665176T3/fi active
- 2018-08-10 PT PT187601687T patent/PT3665176T/pt unknown
- 2018-08-10 DK DK18760168.7T patent/DK3665176T3/da active
- 2018-08-10 BR BR112020002892-4A patent/BR112020002892A2/pt not_active Application Discontinuation
- 2018-08-10 IL IL272556A patent/IL272556B2/en unknown
- 2018-08-10 KR KR1020247014386A patent/KR20240063198A/ko not_active Ceased
- 2018-08-10 CA CA3072240A patent/CA3072240A1/en active Pending
- 2018-08-10 PL PL18760168.7T patent/PL3665176T3/pl unknown
-
2020
- 2020-02-07 MX MX2023005875A patent/MX2023005875A/es unknown
- 2020-02-07 MX MX2024003249A patent/MX2024003249A/es unknown
-
2021
- 2021-09-24 US US17/484,025 patent/US12145943B2/en active Active
-
2023
- 2023-02-23 AU AU2023201059A patent/AU2023201059B2/en active Active
- 2023-07-28 JP JP2023123302A patent/JP7778750B2/ja active Active
-
2024
- 2024-10-16 US US18/917,541 patent/US20250115616A1/en active Pending
-
2025
- 2025-04-28 AU AU2025202936A patent/AU2025202936A1/en active Pending
- 2025-10-06 JP JP2025168516A patent/JP2026012715A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530497A5 (https=) | ||
| CN114072411A (zh) | 作为Wee1抑制剂的嘧啶衍生物 | |
| JP2019502892A5 (https=) | ||
| PH12017500635B1 (en) | Aminopyridyloxypyrazole compounds | |
| SG158875A1 (en) | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | |
| MX2010007604A (es) | Pirimidinas como inhibidores de cinasa. | |
| MX2009012950A (es) | ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS. | |
| WO2009087212A3 (en) | Pyridine derivatives | |
| JO2645B1 (en) | Vehicles | |
| CA2672094C (en) | Methods and apparatus for identifying subject matter in view data | |
| WO2007125331A3 (en) | Amino-ethyl-amino-aryl (aeaa) compounds and their use | |
| JP2021505241A5 (https=) | ||
| JP2013519136A5 (https=) | ||
| CN113906026A (zh) | 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 | |
| EA201070691A1 (ru) | Амидные соединения в качестве активаторов противовирусных препаратов | |
| PH12020550125A1 (en) | Crystalline forms of 3-substituted 1,2,4-oxadiazole | |
| CN114555600A (zh) | 作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物 | |
| PH12017501829A1 (en) | Pharmaceutical formulations | |
| NZ755447A (en) | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer | |
| GB0524814D0 (en) | Compounds | |
| CN111836819A (zh) | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 | |
| UA96627C2 (ru) | Сухой экстракт из pelargonium sidoides ta pelargonium reniforme, способ его получения и продукты на его основе | |
| JP2022536408A5 (https=) | ||
| CN109311817A (zh) | 取代的含氮芳环化合物及其应用 | |
| Hoang et al. | Discovery of 1H-indazole-6-amine Derivatives as Anticancer Agents: Simple But Effective |